Pluto aims to build the next generation of “off-the-shelf” cellular immunotherapies.
Market:
We aim to change the way cancer is treated through unlimited in vitro production of tumor-optimized, functionally enhanced allogenic T cells. The projected market size for allogeneic cell therapy has been estimated as $~10.25B USD.Technology:
Our platform system is the best-in-class for the generation of mature T cells from pluripotent stem cells (PSC). Only PSC can generate off-the-shelf products with the optimal complex gene edits required for targeting solid tumors.Advantages:
- Best-in-class technology for generating mature T cells from a renewable source of induced pluripotent stem cells (iPSC)
- Unlimited cell source
- Unique potential for unlimited gene editing to engineer safer and more effective T cell therapies
Development Stage:
- Pre-clinical
Select Publications:
- UCLA scientists create a renewable source of cancer-fighting T cells | UCLA Newsroom
- Organoid-Induced Differentiation of Conventional T Cells from Human Pluripotent Stem Cells | PubMed.gov
- Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids | PubMed.gov
Contact:
Email: info@plutoimmuno.comPortfolio Companies
- Active Membranes, LLC.
- Avesta76 Therapeutics
- Capacity Bio
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- EarlyDx
- Forcyte Biotechnologies
- Gradient Orthodontics
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- Nanoarmor, LLC.
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Scarless Laboratories
- Sorriso Pharmaceuticals
- Symphony Biosciences
- Vault Pharma
- ViBo Health
- Westwood Bioscience